Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Cancer Immunotherapy Market

4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cancer Immunotherapy Market Analysis and Forecast, 2017–2031

5. Key Insights
5.1. Value Chain Analysis
5.2. Pipeline Analysis
5.3. Cancer Epidemiology
5.4. COVID-19 impact

6. Global Cancer Immunotherapy Market Analysis and Forecast, by Therapy Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Therapy Type, 2017–2031
6.3.1. Monoclonal Antibodies
6.3.2. Immune Checkpoint Inhibitors
6.3.3. PD-1/PD-L1
6.3.4. CTLA-4
6.3.5. Immune System Modulators
6.3.6. Cancer Vaccines
6.3.7. Others
6.4. Market Attractiveness Analysis, by Therapy Type

7. Global Cancer Immunotherapy Market Analysis and Forecast, by Therapeutic Area
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Therapeutic Area, 2017–2031
7.3.1. Lung Cancer
7.3.2. Colorectal Cancer
7.3.3. Breast Cancer
7.3.4. Prostate Cancer
7.3.5. Melanoma
7.3.6. Blood Cancer
7.3.7. Others
7.4. Market Attractiveness Analysis, by Therapeutic Area

8. Global Cancer Immunotherapy Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals
8.3.2. Ambulatory Surgical Centers (ASCs)
8.3.3. Cancer Research Centers
8.3.4. Clinics
8.4. Market Attractiveness Analysis, by End-user

9. Global Cancer Immunotherapy Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region

10. North America Cancer Immunotherapy Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Therapy Type, 2017–2031
10.2.1. Monoclonal Antibodies
10.2.2. Immune Checkpoint Inhibitors
10.2.3. PD-1/PD-L1
10.2.4. CTLA-4
10.2.5. Immune System Modulators
10.2.6. Cancer Vaccines
10.2.7. Others
10.3. Market Value Forecast, by Therapeutic Area, 2017–2031
10.3.1. Lung Cancer
10.3.2. Colorectal Cancer
10.3.3. Breast Cancer
10.3.4. Prostate Cancer
10.3.5. Melanoma
10.3.6. Blood Cancer
10.3.7. Others
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals
10.4.2. Ambulatory Surgical Centers (ASCs)
10.4.3. Cancer Research Centers
10.4.4. Clinics
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Therapy Type
10.6.2. By Therapeutic Area
10.6.3. By End-user
10.6.4. By Country

11. Europe Cancer Immunotherapy Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Therapy Type, 2017–2031
11.2.1. Monoclonal Antibodies
11.2.2. Immune Checkpoint Inhibitors
11.2.3. PD-1/PD-L1
11.2.4. CTLA-4
11.2.5. Immune System Modulators
11.2.6. Cancer Vaccines
11.2.7. Others
11.3. Market Value Forecast, by Therapeutic Area, 2017–2031
11.3.1. Lung Cancer
11.3.2. Colorectal Cancer
11.3.3. Breast Cancer
11.3.4. Prostate Cancer
11.3.5. Melanoma
11.3.6. Blood Cancer
11.3.7. Others
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Ambulatory Surgical Centers (ASCs)
11.4.3. Cancer Research Centers
11.4.4. Clinics
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Therapy Type
11.6.2. By Therapeutic Area
11.6.3. By End-user
11.6.4. By Country/Sub-region

12. Asia Pacific Cancer Immunotherapy Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Therapy Type, 2017–2031
12.2.1. Monoclonal Antibodies
12.2.2. Immune Checkpoint Inhibitors
12.2.3. PD-1/PD-L1
12.2.4. CTLA-4
12.2.5. Immune System Modulators
12.2.6. Cancer Vaccines
12.2.7. Others
12.3. Market Value Forecast, by Therapeutic Area, 2017–2031
12.3.1. Lung Cancer
12.3.2. Colorectal Cancer
12.3.3. Breast Cancer
12.3.4. Prostate Cancer
12.3.5. Melanoma
12.3.6. Blood Cancer
12.3.7. Others
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Hospitals
12.4.2. Ambulatory Surgical Centers (ASCs)
12.4.3. Cancer Research Centers
12.4.4. Clinics
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Therapy Type
12.6.2. By Therapeutic Area
12.6.3. By End-user
12.6.4. By Country/Sub-region

13. Latin America Cancer Immunotherapy Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Therapy Type, 2017–2031
13.2.1. Monoclonal Antibodies
13.2.2. Immune Checkpoint Inhibitors
13.2.3. PD-1/PD-L1
13.2.4. CTLA-4
13.2.5. Immune System Modulators
13.2.6. Cancer Vaccines
13.2.7. Others
13.3. Market Value Forecast, by Therapeutic Area, 2017–2031
13.3.1. Lung Cancer
13.3.2. Colorectal Cancer
13.3.3. Breast Cancer
13.3.4. Prostate Cancer
13.3.5. Melanoma
13.3.6. Blood Cancer
13.3.7. Others
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Hospitals
13.4.2. Ambulatory Surgical Centers (ASCs)
13.4.3. Cancer Research Centers
13.4.4. Clinics
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Therapy Type
13.6.2. By Therapeutic Area
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Cancer Immunotherapy Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Therapy Type, 2017–2031
14.2.1. Monoclonal Antibodies
14.2.2. Immune Checkpoint Inhibitors
14.2.3. PD-1/PD-L1
14.2.4. CTLA-4
14.2.5. Immune System Modulators
14.2.6. Cancer Vaccines
14.2.7. Others
14.3. Market Value Forecast, by Therapeutic Area, 2017–2031
14.3.1. Lung Cancer
14.3.2. Colorectal Cancer
14.3.3. Breast Cancer
14.3.4. Prostate Cancer
14.3.5. Melanoma
14.3.6. Blood Cancer
14.3.7. Others
14.4. Market Value Forecast, by End-user, 2017–2031
14.4.1. Hospitals
14.4.2. Ambulatory Surgical Centers (ASCs)
14.4.3. Cancer Research Centers
14.4.4. Clinics
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Therapy Type
14.6.2. By Therapeutic Area
14.6.3. By End-user
14.6.4. By Country/Sub-region

15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. Amgen, Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Financial Analysis
15.3.1.3. Growth Strategies
15.3.1.4. SWOT Analysis
15.3.2. F. Hoffmann-La Roche Ltd.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Financial Analysis
15.3.2.3. Growth Strategies
15.3.2.4. SWOT Analysis
15.3.3. Bristol-Myers Squibb Company
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Financial Analysis
15.3.3.3. Growth Strategies
15.3.3.4. SWOT Analysis
15.3.4. Merck & Co., Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Financial Analysis
15.3.4.3. Growth Strategies
15.3.4.4. SWOT Analysis
15.3.5. Spectrum Pharmaceuticals
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Financial Analysis
15.3.5.3. Growth Strategies
15.3.5.4. SWOT Analysis
15.3.6. GlaxoSmithKline plc
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Financial Analysis
15.3.6.3. Growth Strategies
15.3.6.4. SWOT Analysis
15.3.7. Pfizer, Inc.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Financial Analysis
15.3.7.3. Growth Strategies
15.3.7.4. SWOT Analysis
15.3.8. AstraZeneca plc
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Financial Analysis
15.3.8.3. Growth Strategies
15.3.8.4. SWOT Analysis
15.3.9. Eli Lilly and Company.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Financial Analysis
15.3.9.3. Growth Strategies
15.3.9.4. SWOT Analysis
15.3.10. Takeda Pharmaceuticals
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Financial Analysis
15.3.10.3. Growth Strategies
15.3.10.4. SWOT Analysis



List of Figures

List of Figures

Figure 01: Global Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2022 and 2031

Figure 02: Global Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2022 and 2031

Figure 03: Global Cancer Immunotherapy Market Value Share Analysis, by End-user, 2022 and 2031

Figure 04: Global Cancer Immunotherapy Market Attractiveness Analysis, by Therapy Type, 2022 and 2031

Figure 05: Global Cancer Immunotherapy Market Attractiveness Analysis, by Therapeutic Area, 2022 and 2031

Figure 06: Global Cancer Immunotherapy Market Attractiveness Analysis, by End-user, 2022 and 2031

Figure 07: North America Cancer Immunotherapy Market Value (US$ Mn) Forecast, 2017–2028

Figure 08: North America Cancer Immunotherapy Market Value Share Analysis, by Country, 2022 and 2031

Figure 09: North America Cancer Immunotherapy Market Attractiveness Analysis, by Country, 2022 and 2031

Figure 10: North America Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2022 and 2031

Figure 11: North America Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2022 and 2031

Figure 12: North America Cancer Immunotherapy Market Value Share Analysis, by End-user, 2022 and 2031

Figure 13: Europe Cancer Immunotherapy Market Value (US$ Mn) Forecast, 2017–2028

Figure 14: Europe Cancer Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 15: Europe Cancer Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2022 and 2031

Figure 16: Europe Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2022 and 2031

Figure 17: Europe Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2022 and 2031

Figure 18: Europe Cancer Immunotherapy Market Attractiveness Analysis, by End-user, 2022 and 2031

Figure 1 9: Asia Pacific Cancer Immunotherapy Market Value (US$ Mn) Forecast, 2017–2028

Figure 20: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 21: Asia Pacific Cancer Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2022 and 2031

Figure 22: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2022 and 2031

Figure 23: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2022 and 2031

Figure 24: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by End-user, 2022 and 2031

Figure 25: Latin America Cancer Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 26: Latin America Cancer Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2022 and 2031

Figure 27: Latin America Cancer Immunotherapy Market Attractiveness Analysis, by Therapy Type, 2022 and 2031

Figure 28: Latin America Cancer Immunotherapy Market Attractiveness Analysis, by Therapeutic Area, 2022 and 2031

Figure 29: Latin America Cancer Immunotherapy Market Attractiveness Analysis, by Therapeutic Area, 2022 and 2031

Figure 30: Latin America Cancer Immunotherapy Market Attractiveness Analysis, by End-user 2022 and 2031

Figure 31: Middle East & Africa Cancer Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 32: Middle East & Africa Cancer Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2022 and 2031

Figure 33: Middle East & Africa Cancer Immunotherapy Market Attractiveness Analysis, by Therapy Type, 2022 and 2031

Figure 34: Middle East & Africa Cancer Immunotherapy Market Attractiveness Analysis, by Therapeutic Area, 2022 and 2031

Figure 35: Middle East & Africa Cancer Immunotherapy Market Attractiveness Analysis, by End-user, 2022 and 2031

List of Tables

List of Tables

Table 01: Global Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapy Type, 2022 and 2031

Table 02: Global Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapeutic Area, 2022 and 2031

Table 03: Global Cancer Immunotherapy Market Value (US$ Mn) Forecast, by End-user, 2022 and 2031

Table 04: Global Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Region, 2022 and 2031

Table 05: North America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Country, 2022 and 2031

Table 06: North America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapy Type, 2022 and 2031

Table 07: North America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapeutic Area, 2022 and 2031

Table 08: North America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by End-user, 2022 and 2031

Table 09: Europe Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022 and 2031

Table 10: Europe Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapy Type, 2022 and 2031

Table 11: Europe Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapeutic Area, 2022 and 2031

Table 12: Europe Cancer Immunotherapy Market Value (US$ Mn) Forecast, by End-user, 2022 and 2031

Table 13: Asia Pacific Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022 and 2031

Table 14: Asia Pacific Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapy Type, 2022 and 2031

Table 15: Asia Pacific Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapeutic Area, 2022 and 2031

Table 16: Asia Pacific Cancer Immunotherapy Market Value (US$ Mn) Forecast, by End-user, 2022 and 2031

Table 17: Latin America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022 and 2031

Table 18: Latin America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapy Type, 2022 and 2031

Table 19: Latin America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by therapeutic Area, 2022 and 2031

Table 20: Latin America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by End-user, 2022 and 2031

Table 21: Middle East & Africa Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022 and 2031

Table 22: Middle East & Africa Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapy Type, 2022 and 2031

Table 23: Middle East & Africa Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapeutic Area 2022 and 2031

Table 24: Middle East & Africa Cancer Immunotherapy Market Value (US$ Mn) Forecast, by End-user 2022 and 2031